Difference between revisions of "Thyroid cancer"
Jump to navigation
Jump to search
(added regimens) |
|||
| Line 17: | Line 17: | ||
|} | |} | ||
| − | ===Regimen | + | ===Regimen {{#subobject:PYV1|Variant=1}}=== |
| − | + | {| border="1" style="text-align:center;" !align="left" | |
| − | <span | + | |'''Study''' |
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 Schlumberger et al. 2015 (SELECT)] | ||
| + | |<span | ||
style="background:#00CD00; | style="background:#00CD00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
| Line 25: | Line 30: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase III</span> | border-style:solid;">Phase III</span> | ||
| + | |[[Thyroid_cancer#Placebo|Placebo]] | ||
| + | |- | ||
| + | |} | ||
*[[Lenvatinib (Lenvima)]] 24 mg PO once per day on days 1 to 28 | *[[Lenvatinib (Lenvima)]] 24 mg PO once per day on days 1 to 28 | ||
**Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive [[Lenvatinib (Lenvima)]] 14 mg PO once per day | **Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive [[Lenvatinib (Lenvima)]] 14 mg PO once per day | ||
| Line 31: | Line 39: | ||
===References=== | ===References=== | ||
| − | # '''Abstract:''' Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K Krzyzanowska, Steven I. Sherman. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). 2014 ASCO Annual Meeting abstract LBA6008. [http://meetinglibrary.asco.org/content/132694-144 link to abstract] | + | <!-- # '''Abstract:''' Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K Krzyzanowska, Steven I. Sherman. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). 2014 ASCO Annual Meeting abstract LBA6008. [http://meetinglibrary.asco.org/content/132694-144 link to abstract] --> |
| − | # [http://www.lenvima.com/pdfs/prescribing-information.pdf Lenvatinib (Lenvima) package insert] | + | # [http://www.lenvima.com/pdfs/prescribing-information.pdf Lenvatinib (Lenvima) package insert] |
| + | # Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. [http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25671254 PubMed] | ||
==Placebo {{#subobject:PYR2|Regimen=1}}== | ==Placebo {{#subobject:PYR2|Regimen=1}}== | ||
| Line 41: | Line 50: | ||
===Regimen {{#subobject:PYV2|Variant=1}}=== | ===Regimen {{#subobject:PYV2|Variant=1}}=== | ||
| − | + | {| border="1" style="text-align:center;" !align="left" | |
| − | <span | + | |'''Study''' |
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 Schlumberger et al. 2015 (SELECT)] | ||
| + | |<span | ||
style="background:#00CD00; | style="background:#00CD00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
| Line 48: | Line 62: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase III</span> | border-style:solid;">Phase III</span> | ||
| + | |[[Thyroid_cancer#Lenvatinib_.28Lenvima.29|Lenvatinib]] | ||
| + | |- | ||
| + | |} | ||
| − | ''No treatment | + | ''No active antineoplastic treatment.'' |
===References=== | ===References=== | ||
| − | #'''Abstract:''' Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K Krzyzanowska, Steven I. Sherman. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). 2014 ASCO Annual Meeting abstract LBA6008. [http://meetinglibrary.asco.org/content/132694-144 link to abstract] | + | <!-- # '''Abstract:''' Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K Krzyzanowska, Steven I. Sherman. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). 2014 ASCO Annual Meeting abstract LBA6008. [http://meetinglibrary.asco.org/content/132694-144 link to abstract] --> |
| + | # Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. [http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25671254 PubMed] | ||
=Medullary thyroid cancer= | =Medullary thyroid cancer= | ||
Revision as of 13:47, 13 August 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
3 regimens on this page
3 variants on this page
|
Differentiated thyroid cancer
Lenvatinib (Lenvima)
| back to top |
Regimen
| Study | Evidence | Comparator |
| Schlumberger et al. 2015 (SELECT) | Phase III | Placebo |
- Lenvatinib (Lenvima) 24 mg PO once per day on days 1 to 28
- Per the package insert, patients with creatinine clearance of <30 mL/min by Cockroft-Gault or Child-Pugh C severe hepatic impairment should receive Lenvatinib (Lenvima) 14 mg PO once per day
28-day cycles, given until progression of disease, or unacceptable toxicity
References
- Lenvatinib (Lenvima) package insert
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. link to original article PubMed
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator |
| Schlumberger et al. 2015 (SELECT) | Phase III | Lenvatinib |
No active antineoplastic treatment.
References
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. link to original article PubMed
Medullary thyroid cancer
Cabozantinib (Cometriq)
| back to top |
Regimen
Level of Evidence: Non-randomized
- Cabozantinib (Cometriq) 140 mg PO once per day, at least 2 hours before or 1 hour after meals
References
- Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. link to original article contains verified protocol PubMed
Placebo
| back to top |
Regimen
Level of Evidence: Phase III
No treatment. Included for reference purposes only.
References
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed
Sorafenib (Nexavar)
| back to top |
Regimen
Level of Evidence: Phase II
- Sorafenib (Nexavar) 400 mg PO BID
References
- Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. link to original article contains verified protocol PubMed
Sunitinib (Sutent)
| back to top |
Regimen
Level of Evidence: Phase II
- Sunitinib (Sutent) 37.5 mg PO once per day
References
- Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed
Vandetanib (Caprelsa)
| back to top |
Regimen #1, Wells et al. 2010 & Wells et al. 2012
Level of Evidence: Phase III
- Vandetanib (Caprelsa) 300 mg PO once per day
Regimen #2, Robinson et al. 2010
Level of Evidence: Phase II, <20 patients reported
- Vandetanib (Caprelsa) 300 mg PO once per day
References
- Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. link to original article contains verified protocol PubMed
- Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. link to original article contains verified protocol PubMed content property of HemOnc.org
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. link to original article contains verified protocol PubMed
Various histologies
Axitinib (Inlyta)
| back to top |
Regimen
Level of Evidence: Phase II
- Axitinib (Inlyta) 5 mg PO BID
References
- Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains verified protocol PubMed
Sorafenib (Nexavar)
| back to top |
Regimen
Level of Evidence: Phase II
- Sorafenib (Nexavar) 400 mg PO BID
References
- Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains verified protocol PubMed
Sunitinib (Sutent)
| back to top |
Regimen
Level of Evidence: Phase II
- Sunitinib (Sutent) 37.5 mg PO once per day
References
- Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. link to original article contains verified protocol PubMed